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Gautam K Malhotra1, Xiangshan Zhao1, Emily Edwards1, Janel L Kopp2, Mayumi Naramura1,3, Maike Sander2,
Hamid Band1,4,5,6 and Vimla Band1,3*Abstract
Background: Identification and characterization of molecular controls that regulate mammary stem and progenitor
cell homeostasis are critical to our understanding of normal mammary gland development and its pathology.
Results: We demonstrate that conditional knockout of Sox9 in the mouse mammary gland results in impaired
postnatal development. In short-term lineage tracing in the postnatal mouse mammary gland using Sox9-CreER
driven reporters, Sox9 marked primarily the luminal progenitors and bipotent stem/progenitor cells within the basal
mammary epithelial compartment. In contrast, long-term lineage tracing studies demonstrate that Sox9+ precursors
gave rise to both luminal and myoepithelial cell lineages. Finally, fate mapping of Sox9 deleted cells demonstrates
that Sox9 is essential for luminal, but not myoepithelial, lineage commitment and proliferation.
Conclusions: These studies identify Sox9 as a key regulator of mammary gland development and stem/progenitor
maintenance.
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Development and maintenance of adult tissues and or-
gans is orchestrated by a pool of resident stem/progeni-
tor cells which are required to meet the needs of tissue
remodeling and regeneration associated with physio-
logical and pathological states. Understanding the mo-
lecular basis of stem/progenitor maintenance during
mammary gland development is of substantial interest
given the physiologically critical role of the organ, the
dynamic nature of the organ with dramatic changes dur-
ing sexual and reproductive cycles, and the extremely
high prevalence of cancer of mammary gland [1-3].
Mammary transplant studies have established the existence
of multipotent mammary stem cells (MaSCs) in the adult* Correspondence: vband@unmc.edu
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unless otherwise stated.mammary gland, with a remarkable capacity to regenerate
a functional organ [4-6]. More recently, fluorescence-
activated cell sorting (FACS) analyses, based on cell surface
markers (e.g., Lin-/CD24+/CD29hi; CD49fhi), has allowed
for enrichment of MaSCs with mammary gland regenera-
tive potential [7,8]. Transplant of a single MaSC isolated
using these approaches can generate a functional mam-
mary gland comprised of both major mammary epithelial
cell lineages: luminal and myoepithelial cells [7,8]. Recent
reports, however, have suggested caution in assigning
MaSC function based on mammary gland regenerative po-
tential in transplantation assays as it may not fully correlate
with MaSC function in situ [9-11]. These studies suggest
the need to verify the transplant-based conclusions using
more definitive in situ lineage tracing studies.
Studies using gene knockout or transgenic expression,
lineage tracing and regenerative models have led to the
identification of a number of molecular pathways that
control mammary development by impinging on MaSCs
and/or progenitor cell populations. Such studies haveal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mammary gland developmental decisions [9,12,13].
We have previously described the in vitro propagation
of immortalized human mammary epithelial stem/pro-
genitor cell lines that can be induced to differentiate
along the luminal or myoepithelial pathway depending
on media conditions [14-16]. An RNA expression screen
of parental cells vs. their myoepithelial progeny identi-
fied a number of genes whose expression was restricted
to bipotent parental cells. Here, we focus on one of these
candidate genes, Sox9 (sex-determining region Y [SRY]-
box 9 protein) which is a high mobility group box tran-
scription factor that has been demonstrated to play
critical roles during embryogenesis and in the develop-
ment, differentiation, and lineage commitment of a
number of organ system [17]. Genetic studies have im-
plicated Sox9 in the maintenance of stem or progenitor
cells in the hair follicle, liver, pancreas, and intestine
[18-23]. These findings, together with our human MaSC
vs. myoepithelial cell expression profiling [14], suggest
that Sox9 may physiologically regulate mammary gland
development and mammary stem/progenitor cell func-
tion. Indeed, in a recent study ectopic expression of
Sox9 together with Slug was shown to be sufficient in
reprograming mature luminal mammary epithelial cells
into MaSCs while Sox9 expression by itself converted
these cells into luminal progenitors [24].
Collectively, the findings presented above are consist-
ent with a physiological role of Sox9 in mammary de-
velopment and MaSC homeostasis. However, this has
not been directly tested. Here, we describe studies
using mammary gland-directed conditional knockout
(cKO) of Sox9 together with Sox9-Cre-mediated activa-
tion of reporters for lineage tracing to directly establish
a novel role of Sox9 in mammary gland development
and maintenance of mammary stem and luminal pro-
genitor cells.
Results
Conditional Sox9 deletion results in defective mammary
gland development
We have previously characterized immortal human mam-
mary epithelial lines that indefinitely maintain stem/pro-
genitor cell characteristics in vitro and these can be
induced to differentiate into luminal or myoepithelial pro-
geny [14-16]. Whole genome RNA expression differences
between parental cells and their myoepithelial progeny
identified Sox9 as one of the transcription factors enriched
in undifferentiated parental cells (Additional file 1: Figure
S1A). Knockdown of Sox9 using shRNA showed its re-
quirement for the proliferation of these stem/progenitor
cell lines (Additional file 1: Figure S1B, C). To further ex-
plore the role of Sox9 in a mouse model, we isolated
mouse mammary epithelial cells from Sox9fl/fl mice andinduced the complete deletion of Sox9 in vitro by infecting
these cells with an adenovirus expressing Cre-GFP or
only GFP as a control) (Additional file 1: Figure S2A).
In keeping with human mammary stem/progenitor cell
line results, in vitro deletion of Sox9 in mouse mam-
mary epithelial cells resulted in a profound inhibition of
proliferation as compared to control cells (Additional
file 1: Figure S2B).
To examine the physiological consequence of Sox9 dele-
tion in the mammary gland, we crossed Sox9fl/fl mice [25]
with mouse mammary tumor virus (MMTV)- Cre mice,
which have been established to promote gene deletion in
the epithelial compartments of the mammary gland [26].
MMTV-Cre; Sox9fl/fl pups allow for mammary gland spe-
cific deletion, allowing an analysis of the impact of Sox9
deletion on mammary gland development.
The mouse mammary gland undergoes substantial de-
velopmental changes during early postnatal life [2]. Com-
parison of whole mounts of mouse mammary glands
derived from three-week old Sox9 cKO mice revealed
clear developmental defects (Figure 1). Compared to con-
trol mammary glands, the cKO mammary gland growth
was stunted with substantially less ductal outgrowths and
side branching. The cKO mammary gland development
continued to lag at 5 weeks of age, with considerably
less secondary ductal branching. Notably, however, cKO
mammary glands at 8 weeks (and beyond; not shown)
displayed minimal or no defects in ductal branching or
the extent of overall growth (Figure 1). Furthermore,
the increased branching and alveologenesis associated
with pregnancy and lactation in Sox9 cKO was compar-
able to that of control mice (Figure 1). Thus, the Sox9
cKO mice show a delay in the development of the mam-
mary gland with a pronounced early phenotype followed
by an apparent recovery.
Sox9 is essential for mouse mammary stem and luminal
progenitor cell function
The gradual recovery of the developmental phenotype
seen in Sox9 cKO mammary glands beyond 8 weeks of
age is suggestive of either a transient role of Sox9, or an
inability of Sox9-null stem/progenitors to contribute to
progeny and compensation by stem/progenitors that did
not undergo Cre-mediated Sox9 deletion due to mosaic
MMTV-Cre mediated gene deletion. We therefore ana-
lyzed the expression of MMTV-Cre in our bi-transgenic
mice. The mammary glands of control mice (MMTV-
Cre; Sox9wt/wt) showed that Cre expression is indeed
mosaic, with expression in ~50% of epithelial cells through-
out development (Figure 2). Importantly, the proportion
of Cre-expressing epithelial cells in the Sox9 cKO mam-
mary glands was markedly diminished (Figure 2). At
3 weeks, when the developmental delay is most pro-
nounced, there is a small percentage of Cre expressing
Figure 1 Deletion of Sox9 results in mammary gland defects in 3 and 5 weeks old mice. Whole mount analysis of mammary glands from
control (MMTV-Cre; Sox9wt/wt) and Sox9 cKO (MMTV-Cre; Sox9fl/fl) mice. Mammary glands were harvested at 3, 5, 8 weeks, mid-pregnancy,
lactation day 1, and lactation day 10 and stained with carmine alum and analyzed under the microscope.
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mary epithelial cells is further diminished by 5 weeks,
and we were unable to find any such cells in 8-week old
Sox9 cKO mice, while such cells were abundant in the
age matched control mice (Figure 2). The gradual lossFigure 2 Sox9 deleted cells are lost over time. Immunostaining of contr
mammary glands cut sections (3, 5, 8 weeks old mice) with Cre antibody (redof Cre-expressing mammary epithelial cells in cKO
mice supports the conclusion that Sox9 expression is
critical for mammary gland development and that Sox9
deleted cells are incapable of contributing to further
mammary gland development.ol (MMTV-Cre; Sox9wt/wt) and Sox9 cKO (MMTV-Cre; Sox9fl/fl) mouse
). Green and blue represent anti-SMA and DAPI staining, respectively.
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due to non-specific staining within the mammary gland.
We tested several anti-Sox9 antibodies (Millipore Cat:
AB5535; LSBio Cat: LS-B5761/29528; Abnova, Cat:
PAB12736; AbCam Cat: ab3697, ab71762, Ab59252) but
were unable to detect specific Sox9 staining in luminal
cells. The antibodies tested showed either no reactivity in
western blotting or IHC staining, or non-specific reactivity
within the myoepithelial cells (that do not express Sox9
mRNA) (Additional file 1: Figure S13A). The most com-
monly used antibody in the literature (Millipore) [23,24,27]
also showed non-specific reactivity with myoepithelial cells
in both western blotting and immunofluorescence assays
(Additional file 1: Figure S3A, B).
Lineage tracing reveals that Sox9-expressing cells are
precursors of both luminal and basal mammary epithelial
compartments, and suggests a role of Sox9 in the
maintenance of luminal progenitor pool
Sox9 has been established to play key developmentally
regulated roles in the maintenance of stem or progenitor
compartments as well as lineage differentiation in many
tissues and organs [17-23]. While analyses using ectopic
Sox9 expression or knockdown are consistent with a
similar functional role of Sox9 in mammary gland devel-
opment, experimental evidence for any such roles
in vivo is currently lacking. Our findings that mammary
gland development is delayed in MMTV-Cre driven
Sox9 cKO mice (Figure 1) strongly suggested a potential
role of Sox9 function in MaSCs and/or lineage-restricted
progenitors. To experimentally assess this, we carried
out lineage-tracing analyses to determine if Sox9 ex-
pressing cells give rise to mature mammary lineages. For
this purpose, we crossed the Sox9-CreERT2 mice, which
express a tamoxifen-inducible CreERT2 fusion under the
control of Sox9 promoter (hence Cre is only expressed
in Sox9+ cells after induction with tamoxifen) [28] with
either CAG-eGFP or ROSA26-LacZ reporter mice [29].
Tamoxifen was administered to adult virgin (>8 weeks)
Sox9-CreERT2; R26R-LacZ or Sox9-CreERT2; CAG-
eGFP mice and mammary glands were analyzed after
72 hours. At 72 hours post-induction, analysis of tissue
sections for GFP+ cells was seen almost exclusively in
the luminal compartment (Figure 3A). Flow cytometry
analyses are concordant with this finding, as the vast
majority of GFP+ cells (shown as red panel) resided
within the CD24hi luminal compartment (Figure 3B).
Notably, GFP+ population represents only a fraction of
the luminal compartment (Figure 3B), suggesting that
the Sox9+ cell progeny seen at this time may correspond
to an intrinsic subpopulation within the luminal com-
partment. We hypothesized that this intrinsic subpopu-
lation may represent luminal progenitors within the
mammary gland.To further assess the nature of the Sox9+ cells within
the luminal compartment, we examined the co-
expression of CD61, a marker of luminal progenitors, on
the CD24hi luminal population [3,30]. When analyzing
all CD24hi (GFP+ and GFP-) cells, we find that there are
distinct CD61hi and CD61lo populations (Figure 3C).
However, when analyzing only the CD24hi;GFP+ popula-
tion (Sox9 expressing luminal cells) we find that the vast
majority of GFP+ cells reside within the CD61hi luminal
progenitor subpopulation (Figure 3D). These results sup-
port the conclusion that Sox9 is expressed within the lu-
minal progenitor population. Notably, when analyzing
the CD24hi;GFP+ population, we did observe a small
fraction of GFP+ cells within the CD24lo/CD29hi com-
partment (Figure 3E) that is known to include bipotent
MaSCs [7,9].
To determine if Sox9 expressing cells represented
bipotent MaSCs with an ability to differentiate into mul-
tiple cell lineages, we performed long term lineage tra-
cing experiments by administered tamoxifen to these
mice and harvesting the mammary glands after 4 weeks.
Staining of histological sections showed that after
4 weeks of propagation, Sox9 expressing progeny (seen
as LacZ+) made up a proportion of both luminal and
myoepithelial layers (Figure 4A). This result was more
clearly established by immunofluorescence staining for
GFP together with anti-smooth muscle actin (SMA)
which helps demarcate the myoepithelial (SMA+) and
luminal (SMA-) layers (Figure 4B). Both SMA+GFP+ and
SMA-GFP+ cells were observed suggesting a common
ancestry. We also prepared single-cell suspensions of
harvested mammary glands and subjected these to flow
cytometry to analyze the distribution of GFP+ cells within
the CD24hi (luminal) and CD24lo (basal) mammary epi-
thelial compartments, the latter including myoepithelial
cells and MaSCs [31]. A substantial fraction of both basal
and luminal compartments was GFP+ (Figure 4C), indicat-
ing that Sox9-expressing precursors gave rise to both of
the major mammary epithelial compartments. Dual stain-
ing for CD29 and CD61 showed that GFP+ progeny in-
cluded both CD61hi luminal progenitors and CD61lo
differentiated luminal cells (Figure 4D).
Finally, we also performed an independent long-term
lineage-trace using a non-inducible Sox9-Cre knock-in
mouse model [32] to assess the contribution of Sox9+
cells to mature lineages. For this purpose, we generated
Sox9-Cre; CAG-eGFP bi-transgenic mice [32,33]. Analysis
of whole mount mammary glands demonstrated uniform
GFP expression throughout the mammary ductal system
in adult virgin (>8 weeks) Sox9-Cre; CAG-eGFP mice
(Figure 5A). Immunofluorescence analyses of mammary
gland sections stained for GFP and myoepithelial marker
SMA revealed uniform GFP expression in both luminal
and myoepithelial layers (Figure 5B). Collectively, our
Figure 3 Short-term linage tracing shows that Sox9 is exclusively expressed in luminal cells. (A). Sox9-CreERT2; CAG-EGFP mice were
injected with tamoxifen. 72 hr after injection, the mice were sacrificed for mammary gland staining and FACS analysis. Sections of the mouse
mammary gland were stained with GFP (green) and myoepithelial cell marker (α-SMA) (red) antibodies and DAPI (staining nuclei, blue). (B) Flow
cytometry analysis of CD24 expression of GFP-positive and -negative cells isolated from above tamoxifen treated mouse mammary glands.
(C). Flow cytometry analysis of all CD24+ luminal cells (both GFP+ and GFP-) isolated from the above tamoxifen treated mouse mammary glands
using CD61 and CD49f expression. This demonstrates that luminal cells of the mammary gland are comprised of CD61+ luminal progenitors
and CD61- differentiated luminal cells. (D). CD61, CD49f flow cytometry analysis of only GFP+ cells isolated from above tamoxifen treated mouse
mammary glands shows that GFP+ cells are mostly CD61+ luminal progenitors. (E) CD24, CD29 flow cytometry analysis of GFP positive cells
isolated from above tamoxifen treated mouse mammary glands.
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cells function as precursors of all mature lineages as well
as luminal progenitors, consistent with the functional role
of Sox9 in bipotent MaSCs and luminal progenitors.
Lineage-tracing analyses of Sox9 cKO mice show loss of
Sox9-null progeny in the luminal but not in the basal/
myoepithelial compartment
To determine the fate of mammary epithelial precursors
in which Sox9 was deleted using MMTV-Cre, we used
further crosses to incorporate the CAG-eGFP and
ROSA-LacZ reporters into MMTV-Cre; Sox9fl/fl strain.
As we observed depletion of Cre-expressing cells in both
luminal and myoepithelial compartments of 8-week old
MMTV-Cre-driven Sox9 conditional KO mice (Figure 2),
we anticipated the lineage-trace to show an absence of
Sox9-null progeny in both mammary cell compartments.
However, whole mount analysis showed uniform LacZ
and GFP staining throughout the mammary glands of 5
and 8 week old mice (Figure 6A-B). Notably, LacZ orGFP staining of histological sections revealed that the pro-
geny of Sox9 deleted precursors was restricted to the
basal/myoepithelial layer with essentially complete absence
from the luminal compartment (Figure 6C-D). FACS ana-
lyses demonstrated that GFP+ progeny was present in both
luminal and basal compartments in the control (MMTV-
Cre; Sox9wt/wt; CAG-eGFP) mice (Figure 6E). In contrast,
the mammary glands of mice with MMTV-driven Sox9 de-
letion showed a near complete absence of GFP+ (sox9-
deleted) progeny in the luminal compartment (Figure 6F),
consistent with staining results (Figure 6C-D). These re-
sults suggest that myoepithelial progeny of Sox9-deleted
precursors are viable while their luminal progeny is not.
Discussion
Sox9 has been established as a key regulator of tissue
stem and progenitor cells during development in several
organ systems [18-22,28], more recently has been linked
to cancer stem cell function [24]. A potential role
of Sox9 in regulating mammary stem/progenitor cell
Figure 4 Long-term linage tracing shows that Sox9 expressing cells are capable of giving rise to both luminal and myoepithelial
lineages (A). X-gal stained tissue section of adult virgin Sox9-CreERT2; R26R-LacZ mammary gland injected with TM and harvested after 4 weeks.
Arrows point to reporter activity in myoepithelial cells. (B). GFP stained tissue section of adult virgin Sox9-CreERT2; CAG-EGFP mammary gland injected
with TM and harvested after 4 weeks. Arrows highlight the progeny of Sox9 expressing cells within the myoepithelial layer (C). Flow cytometry analysis
of CD24, GFP expression of GFP positive and negative cells isolated from above adult virgin mice mammary glands. (D). Flow cytometry analysis of
CD61, CD29 expression of GFP+ cells isolated from above adult virgin mice mammary glands.
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expression and analyses of breast cancer cell lines. How-
ever, a physiological role of Sox9 in mammary gland de-
velopment and mammary stem/progenitor cells remains
unknown. Here, we use a conditional gene deletion ap-
proach to provide in situ evidence for a physiological
role of Sox9 as an important regulator of mammary
gland development. We also carried out short and long
term lineage-tracing analyses to implicate a role for Sox9
in the maintenance of mammary stem cells and luminal
progenitors.
Our conclusion that Sox9 is an essential component of
the mammary gland developmental program is based on
a substantial delay in post-natal mammary gland ductal
elongation and branching in mice with MMTV-Cre di-
rected Sox9 deletion (Figure 1). The defects in develop-
ment are particularly severe at early time points
(3 weeks postnatal) but are followed by gradual recovery,
with essential no defects beyond 8 weeks of age. We hy-
pothesized that recovery from the developmental block
imposed by Sox9 deletion is overcome by the expansion
of mammary epithelial cells in which Sox9 deletion did
not occur, due to the known mosaic expression of
MMTV-Cre that we used (Figure 2). Unfortunately,direct Sox9 staining was not possible due to lack of spe-
cific anti-Sox9 antibodies. Several antibodies that we
tested showed either no or non-specific reactivity in
western blotting, IHC, IF (Additional file 1: Figure S3).
Consequently, we used Cre expression as a surrogate for
Sox9 deletion and found that Sox9 deleted cells are lost
in cKO mice by 8 weeks (Figure 2). Accordingly, no sub-
sequent defects in mammary gland development were
observed during pregnancy and lactation. These results
suggest that Sox9 deletion puts the precursors of mam-
mary epithelium at a developmental disadvantage. Our
efforts at conditional Sox9 deletion in the mammary
gland using a K14-Cre, which is active during embryonic
mammary placode stage [34], were not feasible due to
perinatal lethality of the successfully targeted mice.
However, the absence of mammary gland in a rare
short-term survivor confirmed conclusions reached
based on the use of MMTV-Cre driven Sox9 knockout
mice (data not shown). Our results are reminiscent of
more severe phenotypes of gene deletion using K14-Cre
vs. MMTV-Cre, reported for GATA-3 deletion [30]. The
inducible model presented here provides a tractable sys-
tem to further examine the cellular and molecular basis
of Sox9 function in the mammary gland.
Figure 5 Non-inducible long-term linage tracing shows that Sox9 is expressed in luminal and myoepithelial cells. A non-inducible Sox9-Cre
knock-in mouse model was used to assess the contribution of Sox9+ cells to mature lineages. Sox9-Cre mice were crossed with CAG-EGFP mice.
Sox9-Cre; CAG-EGFP mammary gland cut sections were stained with anti-GFP (green) and α-SMA (red) antibodies. DAPI staining is blue. (A) GFP
staining shows Sox9 expressing cells contribute to both luminal and myoepithelial lineages. (B) α-SMA (red) is used to highlight the myoepithelial cells.
Figure 6 Sox9 deleted luminal cells are lost over time. (A). LacZ staining of whole mount mammary glands from 5 week old Sox9 cKO (R26R;
MMTV-Cre; Sox9fl/fl) mouse. (B). GFP in whole mount 8 week old Sox9 cKO (CAG-EGFP; MMTV-Cre; Sox9fl/fl) was visualized with fluorescence microscope.
(C). Section of mammary glands from 5-week old Sox9 cKO (R26R; MMTV-Cre; Sox9fl/fl) mouse, stained with X-gal. (D). Section of mammary glands from
8 week old Sox9 cKO (CAG-EGFP; MMTV-Cre; Sox9fl/fl) mouse, immuno-labeling with anti-GFP (green) and anti-α-SMA (red) antibodies. (E). CD24, GFP
FACS analysis of cells isolated from control (CAG-EGFP;MMTV-Cre; Sox9wt/wt) mouse mammary glands. (F). CD24, GFP Flow cytometry analysis of cells
isolated from Sox9 deletion (MMTV-Cre; Sox9fl/fl; CAG-EGFP) mouse mammary glands.
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development revealed by our conditional knockout stud-
ies, we considered the possibility that Sox9 is important
for the function of mammary stem/progenitor popula-
tions as these are the sources of developmental growth
and expansion of the mammary gland. To test this possi-
bility in an unbiased manner, we carried out lineage-
tracing studies using a Sox9-directed Cre to turn on
reporters that allowed us to track the progeny of Sox9-
expressing precursor populations. When such studies
were carried throughout embryonic development (using
a non-inducible Sox9-Cre), all mammary epithelial cells,
including the luminal and myoepithelial/basal cell layers,
were uniformly positive for reporter expression (Figure 5).
In keeping with this result, a four week chase following
induction of a tamoxifen-inducible Sox9-CreERT2 driver
in postnatal mice led to the appearance of the progeny
of Sox9-expressing precursors in both luminal and myoe-
pithelial/basal cell populations of the mammary gland
(Figure 4). These studies suggest that Sox9 expression
marks an early bi-potent MaSCs, however, we cannot pre-
clude the possibility that Sox9 may be expressed in both
luminal and myoepithelial restricted progenitors. In view
of the defects in mammary development upon Sox9 dele-
tion (discussion above), we suggest that Sox9 is an import-
ant regulator of the developmental program of MaSCs.
Furthermore, we have previously published a report of iso-
lating and immortalizing a human MaSC line that is able
to differentiate into the myoepithelial lineage [35]. Western
blot data confirms that Sox9 expression is markedly higher
in immortal human MaSC lines vs. their progeny differ-
entiated along the myoepithelial lineage (Additional file 1:
Figure S2). Furthermore, Sox9 deletion results in inhib-
ition of proliferation in in both human mammary epithe-
lial and mouse mammary epithelial cells (Additional file 1:
Figure S1 and S2).
Several recent studies support our conclusion that
Sox9 provides a critical function in maintaining MaSCs.
For example, ectopic co-expression of Sox9 and Slug re-
programed mature luminal mammary epithelial cells
into MaSCs capable of generating mammary gland-like
growths upon transplant [24]. Down-regulation of Wnt-
1-induced signaling protein-2 (WISP2) in relatively well-
differentiated MCF7 breast cancer cell line promoted a
cancer stem-like cell phenotype with upregulation of
SOX9 [36]. In another study, expression of miR-140,
which targeted Sox9 directly, was seen to be lower in
breast cancer patients and cancer stem cells and was as-
sociated with increased SOX9 expression [37]. High
Sox9 expression in basal-like breast cancer correlates
with poor prognosis and activation of Wnt/β-catenin
pathway, and SOX9 silencing reduced cell proliferation
and invasion [38]. Furthermore, overexpression in cell
lines increased Wnt signaling transgenic overexpressionin murine mammary glands increased secondary ductal
branching [38]. As Sox9 is a Wnt target in other stem
cell systems [39], and accumulating evidence suggest a
key role of Wnt/β-Catenin pathway in the maintenance
of MaSCs [9,40], it is reasonable to postulate that Sox9
is an important component of MaSC maintenance by
Wnt/β-Catenin and potentially other pathways.
Notably, two significant findings in our study imply a
more important role of Sox9 in the regulation of luminal
progenitors. First, short term lineage-tracing almost exclu-
sively marked the luminal mammary epithelial layer, and
FACS analyses using CD61 confirmed the marked popula-
tion to be luminal progenitors (Figure 3). Second, when
we carried out lineage tracing in the context of Sox9 dele-
tion induced by MMTV-Cre, we noted that progeny of
Sox9-deleted precursors was absent from the luminal epi-
thelial compartment but such cells were still present
within the myoepithelial/basal compartment and may rep-
resent the progeny of restricted myoepithelial progenitors
that underwent Sox9 deletion (Figure 6). These results
suggest that Sox9 function may be particularly critical for
the development of the luminal lineage. Selective labeling
of luminal progenitors upon short-term tracing is consist-
ent with this conclusion. This idea is further supported by
recent findings that ectopic Sox9 expression in mature
mammary epithelial cells converts these into cells express-
ing markers of luminal progenitors [24].
Taken together, the findings presented in this paper
demonstrate a physiological role of Sox9 in mammary
gland development. Our results, considered in light of re-
cent publications, implicate Sox9 as a key regulator of the
maintenance of mammary stem cells and luminal progeni-
tors. With emerging evidence that Sox9 may contribute to
maintenance of breast cancer stem cells, the inducible
Sox9 deletion model and the insights presented here
should facilitate future efforts to validate Sox9 as a bio-
marker or therapeutic target in breast cancer.
Conclusion
In summary, in this study, we show that Sox9 expression is
restricted to luminal progenitors and bipotent basal stem/
progenitor cells in the postnatal mouse mammary gland.
Long-term lineage tracing studies demonstrated that Sox9+
precursors give rise to both luminal and myoepithelial cell
lineages. Conditional knockout of Sox9 in the mouse mam-
mary gland results in impaired postnatal development. In
vitro knockout SOX9 impaired mouse mammary epithelial
proliferation. Indicate Sox9 is an essential regulator of
mouse mammary stem/progenitor cells.
Methods
Mice
All animal protocols were reviewed and approved by
the Institutional Animal Care and Use Committee at the
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knock-in mice were a generous gift from Dr. Elaine
Fuchs, Rochester, NY. Sox9-CreERT2 mice were gener-
ated in the Sanders laboratory as described [28]. For
conditional deletion, Cre recombinase was expressed
under the control of the mouse mammary tumor virus
(MMTV) (Line A and D) promoter [26]. Sox9fl/fl and
Rosa26fl-STOP-fl-β-geo (R26R) mice were obtained from the
Jackson Laboratory (013106 and 003474 respectively).
CAG-CAT-eGFP reporter transgenic mice have been
previously described [33].
Floxed mice were bred with MMTV-Cre (Line A and D)
[26] to generate heterozygous Cre; Sox9fl/+ mice; which
were then bred with Sox9fl/fl mice to obtain Cre; Sox9fl/fl,
Cre; Sox9fl/+; and non-transgenic Sox9fl/fl mice. These mice
were then intercrossed with either R26R or CAG-eGFP
mice to trace the fate of Sox9 deleted cells.
In Vivo tamoxifen induction
Tamoxifen (Sigma T5648) was dissolved in corn oil
(Sigma C8267) at a concentration of 20 mg/ml. For in-
ducible lineage tracing studies, Sox9-CreERT2; R26R or
Sox9-CreERT2; CAG-eGFP mice were injected intra-
peritoneally with tamoxifen at 5 mg per 40 g body
weight. Mice were injected 3 times, once every other day
unless otherwise noted. A minimum of n = 3 mice were
analyzed for each time point. Adult virgin Sox9-creER
mice were used for those experiments.
Histology and whole mount analysis
For histological examination, the 9th inguinal mammary
glands were harvested at various developmental stages and
fixed in 10% neutral buffered formalin (Sigma HT501128)
for 24 hrs. The glands were paraffin embedded, sectioned
(4 μm) and stained with either hematoxylin/eosin or anti-
bodies discussed below.
For whole mount analysis, the 4th inguinal mammary
glands were harvested at various developmental stages
and fixed in Carnoy’s solution for 3-5 hours followed by
incubation in acetone overnight. The following day, mam-
mary glands were rehydrated and stained in carmine alum
overnight. Finally, the glands were dehydrated, cleared in
xylenes or Histo-clear, and mounted with Omnimount
(National Diagnostics). For LacZ staining of whole mount
mammary glands, the gland was fixed in 2% paraformalde-
hyde, 0.25% glutaraldehyde, 0.01% NP-40 in PBS for 1-2
hours. The glands were then washed 3 × 30 min. with
2 mM magnesium chloride, 0.01% sodium deoxycholate
and 0.2% NP-40 in PBS. Finally, the glands are stained in
the above wash solution supplemented with 30 mM potas-
sium ferricyanide, 30 mM potassium ferrocyanide, and
1 mg/ml X-gal overnight at 30°C. After appropriate LacZ
staining, the glands are washed, cleared in 2:1 benzyl
benzoate:benzyl alcohol (BABB), mounted and imaged.The glands were counterstained with carmine alum and
mounted with Omnimount. For eGFP visualization, mam-
mary glands were harvested immediately after the animal
was sacrificed, cleared in BABB, and visualized. Following
visualization, glands were fixed and stained with carmine
alum, as described above.
Mammary epithelial cell isolation and flow cytometry
Mouse mammary epithelial cell isolation was carried out as
described [31]. In short, mice are individually culled and
both sets of the second, third, and fourth mammary glands
are aseptically removed. The lymph node is removed from
the fourth mammary glands, and all glands are transferred
to a 50 ml conical tube with Leibowitz L15 medium (L15)
supplemented with 10% fetal bovine serum (FBS). The
glands are finely chopped (100 μm) using the McIlwain tis-
sue chopper and transferred to a 50 ml conical tube con-
taining 35 ml of serum free L15, 100 mg of collagenase A,
and 50 mg of trypsin. The chopped tissue is incubated at
37°C with slight agitation for one hr. After the incubation
the mixture is centrifuged at 250 g to remove the fat and
isolate organoids and single cells. The mixture is then
washed twice with red blood cell lysis buffer. To remove
most of the mammary fibroblasts, the mixture is resus-
pended in DMEM and plated in large T-75 flasks incubated
at 37°C for one hour to allow fibroblasts to attach. Finally,
after the one hour incubation, the supernatant containing
epithelial organoids was plated in DFCI medium [41] to
generate bulk cultures. For single cell isolation, the orga-
noids were further processed by enzymatic disassociation
using trypsin and DNAse I. The single cells were then
strained through a 0.45 μm filter and counted. Cells
were then used for flow cytometry analysis or in vitro
propagation assays. Cells were first stained with biotin label
antibodies for CD45, CD31, and Ter119 (all from BD bio-
science). Subsequently, the cells were washed and stained
with a cocktail of antibodies including Streptavidin-
Alexa-350 (Invitrogen), CD24-BV421 (BD), CD29-PE-Cy7
(eBioscience), CD49f-APC (Biolegend), and CD61-PE (BD),
followed by analysis on a BD FACS Aria II. For cell propa-
gation assays, cells were cultured in DFCI media and in-
fected with either Adeno-Cre-GFP or Adeno-GFP. GFP
expressing cells were isolated by FACS and plated at 1x104
cells per well for proliferation assay. Cells were counted
every other day using a coulter counter.
Additional file
Additional file 1: Figure S1. Sox9 knockdown inhibits proliferation in
human mammary epithelial stem/progenitor cells. (A), Sox9 protein
expression in human mammary epithelial stem/progenitor ( MaSCs)
and myoepithelial progenitor cells (MPCs) using western blotting with
anti-Sox9 antibody. (B), MaSCs expressing scrambled (control) or Sox9
shRNA using western blotting with anti-Sox9 antibody. (C), Proliferation
curves of MaSCs control or upon Sox9 shRNA knockdown. Experiment
Malhotra et al. BMC Developmental Biology  (2014) 14:47 Page 10 of 11was carried out three times. A representative figure from one experiment
with Mean + SD of three replicates is shown. Figure S2. Sox9 deletion in
Sox9fl/fl mammary epithelial cells inhibits proliferation. (A), mammary
fibroblasts or mammary epithelial cells from Sox9fl/fl mice were infected
with adenovirus GFP (control) or Cre-GFP (Sox9 KO). Sox9 protein
expression was analyzed by western blotting using anti-Sox9 antibody.
(B), Proliferation over days was assessed in Sox9fl/fl mammary epithelial
cells infected with adenovirus Cre (red) and GFP (blue). Figure S3. Western
blotting and immunostaining with several anti-Sox9 antibodies. (A), Lysates
from human mammary stem/progenitor ( stem) and myoepithelial (myo)
cells (known to be negative for Sox9 mRNA expression) were examined
for Sox9 protein by western blotting. Please note, several non-specific
bands were observed in all antibodies tested with the exception of
one antibody (ab71762) which did not show any immunoreactivity in
western blotting. Antibodies tested include Millipore Cat: AB5535; LSBio
Cat: LS-B5761/29528; Abnova, Cat: PAB12736; AbCam Cat: ab3697,
ab71762, Ab59252. (B), Formalin fixed paraffin embedded mammary
gland cut sections were prepared from MMTV-Cre; Sox9fl/fl; CAG-eGFP
mice and were co-stained with α-GFP (green) and α-Sox9 (red) antibodies
(Millipore). Myoepithelial cells, which are clearly deleted for Sox9 (as
demonstrated by their GFP expression), are also staining positive for
Sox9, which is consistent with the non-specific immunoreactivity seen
in western blotting. DAPI (blue) was used for nuclear counterstaining.Abbreviations
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